🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Recently, Recursion CFO Ben Taylor presented at an AI in Biotech seminar hosted by investment firm Aescap where he explained how we're putting tech first and building a new business model for biotech. 🔹 Key insights: ◾ How Recursion is using AI and automation to shift the

Saving the really hard problems for humans. Speaking at Google Cloud's life-sciences roundtable last week, Recursion CTO Ben Mabey shared how TechBio companies are uniquely positioned to capitalize on AI agents. As reported by Brian Buntz in R&D World, Recursion leverages complex

We’re looking forward to connecting with the people and companies driving London’s tech revolution at London Tech Week next week. With our London office (opened in 2024) and labs and offices in Oxford and Milton Park, we’re proud to be part of this vibrant innovation ecosystem.

Recursion executives will participate in three upcoming investor conferences to discuss how we’re leveraging AI and machine learning to drive meaningful improvements in the speed, cost and efficiency of drug discovery and development. ◾ Thurs., June 5, Recursion CFO Ben Taylor

Today, we’re announcing an important step forward in modeling binding affinity alongside Massachusetts Institute of Technology (MIT) and a research team led by Regina Barzilay. Boltz-2 is the first open-source co-folding model to combine protein structure and binding affinity predictions – measuring how strongly a

The NVIDIA #GTCParis conference is underway, and we’re on site to help spread the word about Boltz-2, the new protein binding affinity model just released in partnership with Massachusetts Institute of Technology (MIT). Last week, we announced the release of Boltz-2 – a powerful new AI model from researchers at MIT

Open science, activated. Since the release of Boltz-2 last Friday – the new open-source protein structure and protein binding affinity model from Massachusetts Institute of Technology (MIT) and Recursion – we’ve been introducing the model to the broader community and the reception has been terrific. 🔹At #GTCParis

Join us at BIO! On Tues., June 17, -2:45pm ET, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will present at the Biotechnology Innovation Organization International Convention in Boston on the panel “Computational Drug Design: Benchmarking Bold Bets, Breakthroughs, and

Last week, Recursion CFO Ben Taylor spoke with Salveen Richter, biotech analyst at Goldman Sachs at the Goldman Sachs 46th Annual Healthcare Conference in Miami. They discussed validation points for the Recursion Operating System, pipeline advances, and how we drive value from

Using AI to unlock new possibilities in clinical research and improve patient outcomes. Recursion has joined the Council for Responsible Use of AI in Clinical Trials, launched today from Advarra, along with leaders from Sanofi and Velocity Clinical Research, Inc., to drive

“When you see the power of these technology tools, it makes it really hard not to feel like there’s going to be an exponential shift in this field.” Recently, cofounder and CEO Chris Gibson sat down with David Bearss, cofounder and CEO of Halia Therapeutics and host of the Good

Two weeks ago, Kelly Zalocusky, Senior Director of Computational Biology at Recursion and site lead for our London office, joined a panel at London Tech Week to discuss “AI in Action.” The discussion – which featured moderator Sara El-Hanfy, Head of AI & ML at Innovate UK, along

We had a great turnout for the 2025 Molecular Machine Learning Conference (#MoML) at Mila - Institut québécois d'IA. Sponsored by Recursion and Valence Labs along with Genesis Therapeutics and Braidwell, the annual event convenes researchers from academia and industry to discuss how ML methods can

Last week, Recursion CFO Ben Taylor and Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD spoke with Peter Lawson, a biotech analyst at Barclays Bank. They discussed Recursion’s 3 main areas of differentiation (end-to-end platform, proprietary data, and wet lab-dry lab

x.com/i/article/1938…